Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 3/20 | 0.38 |
| ▸ | FNTA | P49354 | 3/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.31 |
| ▸ | MVD | P53602 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13227563 | 0.73 | P2RY2 (0.39) | BTN3A1P2RY2P2RY4 | |
| SCHEMBL13113679 | 0.73 | P2RY2 (0.39) | BTN3A1P2RY2P2RY4 | |
| SCHEMBL2034253 | 0.71 | BTN3A1 (0.47) | BTN3A1FNTAPGGT1BFNTBMVD | |
| SCHEMBL13101853 | 0.68 | BTN3A1 (0.33) | BTN3A1 | |
| SCHEMBL2034053 | 0.67 | BTN3A1 (0.50) | BTN3A1FNTAPGGT1BFNTBMVD | |
| SCHEMBL13226751 | 0.67 | BTN3A1 (0.37) | BTN3A1FNTAPGGT1BFNTBP2RY2 | |
| SCHEMBL13226460 | 0.67 | BTN3A1 (0.37) | BTN3A1FNTAPGGT1BFNTBP2RY2 | |
| SCHEMBL21705925 | 0.66 | — | — | |
| SCHEMBL29233723 | 0.65 | ALOX15 (0.34) | — | |
| SCHEMBL4946200 | 0.65 | BTN3A1 (0.40) | BTN3A1MVD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11623940-B2 | Methods of nucleic acid synthesis comprising polyphosphate containing species | Nuclera Nucleics Ltd. (GB) | 2023-04-11 | — | — | US | disclosed |
| US-20200270296-A1 | Novel Use | Nuclera Nucleics Ltd. (GB) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270296-A1 | Novel Use | RNGTT, MTAP, NUDT1 | BTN3A1 1507/4885FNTA 716/4885PGGT1B 1990/4885 |
| US-11623940-B2 | Methods of nucleic acid synthesis comprising polyphosphate containing species | RNGTT, NUDT1, MTAP | BTN3A1 2702/4885FNTA 544/4885PGGT1B 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.